Effect of Intensive Compared With Standard Glycemia Treatment Strategies on Mortality by Baseline Subgroup Characteristics
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial
Article Figures & Tables
Figures
- Figure 1
Demographic characteristics and medical history. HRs are shown for all-cause mortality in intensive versus standard glycemia groups within demographic and medical history subgroups, adjusted for the study stratification factors: 1) history of CVD (except for the analysis of CVD variables), 2) assignment to the Lipid or Blood Pressure trial (each trial had different eligibility criteria), 3) assignment to Lipid trial and randomized to fenofibrate, and 4) assignment to the Blood Pressure trial and randomized to the intensive blood pressure intervention.
- Figure 2
Medication and laboratory tests. HRs are shown for all-cause mortality in intensive versus standard glycemia groups within the medication and laboratory tests subgroups adjusted for the study stratification factors: 1) history of CVD (except for the analysis of CVD variables), 2) assignment to the Lipid or Blood Pressure trial (each trial had different eligibility criteria), 3) assignment to Lipid trial and randomized to fenofibrate, and 4) assignment to the Blood Pressure trial and randomized to the intensive blood pressure intervention.
- Figure 3
A1C and all-cause mortality. Spline curves displaying the log of the HR for all-cause mortality by treatment and baseline A1C are shown. All HRs are with respect to standard glycemia with baseline A1C of 7.0. The bold line represents the intensive treatment group, the finer line the standard group, and the colored lines the 95% CIs.
Tables
- Table 1
Baseline variables
Demographics Medical history Medications Lab tests Age, race/ethnicity, sex, lives alone, clinical network, BMI, waist circumference, education, year randomization Prior CVD event, prior coronary heart failure, diabetes duration, history of neuropathy, peripheral neuropathy, retinal laser/surgery, visual acuity, smoking, depression, blood pressure, electrocardiogram Sulfonylureas, metformin, thiazolidinediones, any insulin HCTZ, ACE inhibitors, β-blockers, calcium-channel blockers, fibrates, statins, aspirin, antidepressants A1C, LDL, HDL, triglyceride, serum creatinine, glomerular filtration rate (modified diet renal disease), urinary albumin-to-creatinine ratio Demographics: age (<65, 65–69, 70–74, ≥75 years), race/ethnicity (Hispanic, white, black, or other), lives alone (vs. with others), clinical center network (7 CCNs), BMI (<30, 30–34, ≥35 kg/m2), waist circumference (<96.7, 96.7–106.6, 106.7–116, ≥116.1 cm), education (<high school, high-school graduate, attended some college or technical school, college graduate), year of randomization into ACCORD (2001–2005). Medical history: diabetes duration (0–5, 6–10, 11–15, ≥16 years), history of neuropathy/nerve problems (“Has the participant ever been told by a physician that he or she has neuropathy/nerve problems”: yes/no), peripheral neuropathy (pedal amputation or a score >2 on the clinical examination portion of the MNSI), visual acuity (<20/40, 20/20–20/40, ≥20/20), smoking status (current, former, never), blood pressure (<135, ≥135), electrocardiogram selected variables (any gross abnormalities, evidence of prior infarction, Q-T interval on electrocardiogram corrected for heart rate [QTc]). Medication use: yes/no at baseline. Laboratory variables: A1C (<7.5, 7.5–8.4, ≥8.5%), LDL cholesterol (<100, 100–119, ≥120 mg/dl), HDL cholesterol (quartiles, mg/dl), triglycerides (<300, ≥300 mg/dl), serum creatinine (0.1–1.0, >1 mg/dl), glomerular filtration rate (modified diet renal disease) (quartiles ml/min), urinary albumin-to-creatinine ratio (<30, 30–300, ≥300 mg/g). HCTZ, hydrochlorotiazide.
In this Issue
